Published in Medical Letter on the CDC and FDA, June 5th, 2005
"An approach to endotoxin (lipopolysaccharide [LPS]) blockade makes use of the ability of lipoproteins, via surface phospholipids, to bind and neutralize LPS. The aim of the present study was to determine whether the intravenous administration of a protein-free, phospholipid-rich emulsion is an effective method for neutralizing the effects of LPS in healthy persons. This was a double-blind, placebo-controlled study in 20 volunteers," investigators in the United States report.
"Volunteers received Escherichia coli endotoxin (2 ng/kg) intravenously 2 hours into a 6-hour...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA